Login

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q1 FY2017
As of Mar 31, 2017
Q4 FY2016
As of Dec 31, 2016
Q3 FY2016
As of Sep 30, 2016
Q2 FY2016
As of Jun 30, 2016
Q1 FY2016
As of Mar 31, 2016
Q4 FY2015
As of Dec 31, 2015
Q3 FY2015
As of Sep 30, 2015
ASSETS
Current assets
Cash and cash equivalents
Deferred offering costs
Cash and cash equivalents held in trust account, interest income available for taxes
Accrued interest receivable held in trust account
Prepaid expenses
Total current assets
Cash and cash equivalents held in trust account, restricted
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued expenses
Note payable to related party
Notes payable to related parties
Total current liabilities
Long term liabilities
Notes payable to related parties
Deferred underwriting fee
Total liabilities
Common stock, subject to possible redemption, 30,775,821 and 30,810,131 shares at redemption value at March 31, 2017 and December 31, 2016, respectively
Stockholders' equity
Preferred stock, $.0001 par value; 1,000,000 shares authorized; none issued and outstanding
Common stock, $.0001 par value; 120,000,000 shares authorized; 9,849,179 and 9,814,869 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders’ equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support